Jeremy Chrisp

Beta Therapeutics Pty Ltd. develops new diabetes therapeutics based on key discoveries. It generates preventative and potentially curative therapies for the people who suffer from diabetes. The company was founded by Keats Nelms, Chris Parish and Charmaine Simeonovic in 2011 and is headquartered in Canberra, Australia.

EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia.

Beta Therapeutics Pty Ltd. develops new diabetes therapeutics based on key discoveries. It generates preventative and potentially curative therapies for the people who suffer from diabetes. The company was founded by Keats Nelms, Chris Parish and Charmaine Simeonovic in 2011 and is headquartered in Canberra, Australia.

Beta Therapeutics Pty Ltd. develops new diabetes therapeutics based on key discoveries. It generates preventative and potentially curative therapies for the people who suffer from diabetes. The company was founded by Keats Nelms, Chris Parish and Charmaine Simeonovic in 2011 and is headquartered in Canberra, Australia.

Beta Therapeutics Pty Ltd. develops new diabetes therapeutics based on key discoveries. It generates preventative and potentially curative therapies for the people who suffer from diabetes. The company was founded by Keats Nelms, Chris Parish and Charmaine Simeonovic in 2011 and is headquartered in Canberra, Australia.